Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 458 participants.
Also called NCT03015220
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 458 participants
- Sponsor
- Registry
-
NCT03015220
-
- Main results
- Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT03015220. Randomized; no masking; primary purpose treatment. Start 2017-01-10 (actual); primary completion 2018-07-12 (actual). Results posted on 2019-12-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
- Acronym
- PIONEER 10
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Dulaglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03015220- Content hash
9ff7898d5b1ab82c88314ad9b6afc19b749bf2237d5b9c8e415fdb23008e0882